Akums Drugs & Pharmaceuticals Limited: A Deep Dive into Q3 FY26 Performance

Akums Drugs & Pharmaceuticals Limited has delivered a robust performance in the third quarter of fiscal year 2026, showcasing strong operational execution across its key segments. The company reported an operating revenue of INR 1,160 crore, marking a significant 14.8% year-on-year growth. This healthy top-line expansion was complemented by a 21.0% increase in Adjusted EBITDA, reaching INR 147 crore, and a 2.1% rise in Adjusted PAT to INR 68 crore. The results underscore Akums' ability to navigate a dynamic market environment while focusing on strategic growth and operational efficiencies.

The quarter's performance was largely propelled by the Contract Development and Manufacturing Organization (CDMO) business, which continues to be the bedrock of Akums' operations. The CDMO segment registered an impressive 16.3% year-on-year growth, driven by strong volumes and improved capacity utilization. This segment alone contributed 79.0% to the total operating revenue, highlighting its dominant role. The international branded formulation business also demonstrated significant momentum, with an 18.0% year-on-year revenue growth, benefiting from demand recovery in key markets. However, the API business continued to face headwinds due to persistent pricing softness, although the pace of decline moderated. Similarly, the trade generics segment is undergoing portfolio rationalization to mitigate losses.

Financial Highlights: Q3 FY26 vs. Q3 FY25

Strategic Growth and Operational Excellence

Akums is actively pursuing several strategic initiatives to bolster its global footprint and enhance operational capabilities. The European CDMO project is advancing as per schedule, with the company having secured EU GMP accreditation for its oral liquids facility (Plant 2) and a renewal for Plant 1. This crucial regulatory milestone paves the way for commercial supplies to Europe, projected to commence in FY28, with an anticipated annual revenue run rate of EUR 35 million. This expansion into regulated markets is a testament to Akums' commitment to global quality manufacturing standards.

Another significant international venture is the Zambia project, which remains firmly on track. Commercial supplies from Akums' Indian plants are expected to begin in H1 FY27, contributing an estimated $25 million in revenue annually for calendar years 2026 and 2027. Concurrently, the company is planning the erection and commissioning of a local facility in Zambia, expected to be operational in approximately two years. These projects underscore Akums' ambition to establish itself as a global pharmaceutical player.

On the operational front, Akums is embracing digital transformation to drive efficiency. The company has initiated its SAP S/4HANA transformation to streamline business processes and implemented Darwinbox to enhance employee experience and automate HR functions. These initiatives are designed to improve real-time analytics and overall operational effectiveness, preparing the organization for future growth.

Navigating Challenges and Future Outlook

While the CDMO and international branded formulation segments are thriving, Akums is proactively addressing challenges in its API and trade generics businesses. The API segment has been impacted by pricing softness, leading to negative EBITDA. In response, management is implementing portfolio rationalization and disciplined cost management initiatives to contain losses and improve sequential performance, with an ultimate goal of achieving breakeven. Similarly, the trade generics segment is undergoing strategic consolidation to reduce losses.

Capacity utilization has improved to 47%, driven by strong volume growth, leading to operating leverage benefits. The new injectable facility, commercialized in phases, is currently at a relatively low utilization but is expected to ramp up significantly in Q2 and Q3 of the next financial year, contributing to the overall injectable CDMO business. Despite a volatile business environment, Akums remains focused on its long-term growth drivers, including innovation, operational efficiency, cost controls, and strategic partnerships. The company's robust cash surplus of INR 1,573 crore and free cash flow of INR 944.5 crore provide a strong financial foundation for these strategic endeavors.

Segmental Performance: Q3 FY26 vs. Q3 FY25

Akums Drugs & Pharmaceuticals Limited's Q3 FY26 performance reflects a company strategically positioning itself for sustained growth. By leveraging its strong CDMO capabilities, expanding into international markets, and enhancing operational efficiencies through digital initiatives, Akums is building a resilient business model. The disciplined approach to managing underperforming segments and a clear focus on long-term value creation instill confidence in its future trajectory.